Spatial dose distributions in solid tumors from 186Re transported by liposomes using HS radiochromic media

Medina, Luis Alberto; Goins, Beth; Rodríguez‐Villafuerte, M.; Bao, Ande; Martínez‐Dávalos, A.; Awasthi, Vibhudutta; Galván, Olga O.; Santoyo, Cristina; Phillips, William T.; Brandan, M.E.

doi:10.1007/s00259-006-0297-x

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiance before and after tumor insonation with systemic and intratumoral injection is quantified. While systemic injection is desirable, local injection and activation provide an opportunity to increase drug concentration and assess release from the capsule [30, 31]. …”

Section: Introductionmentioning

confidence: 99%

Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system

Kheirolomoom

Kruse

Qin

et al. 2010

Journal of Controlled Release

View full text Add to dashboard Cite

To provide a continuous and prolonged delivery of the substrate D-luciferin for bioluminescence imaging in vivo, luciferin was encapsulated into liposomes using either the pH-gradient or acetategradient method. Under optimum loading conditions, 0.17 mg luciferin was loaded per mg of lipid with 90-95% encapsulation efficiency, where active loading was 6 to 18-fold higher than obtained with passive loading. Liposomal luciferin in a long-circulating formulation had good shelf stability, with 10% release over 3-month storage at 4°C. Pharmacokinetic profiles of free and liposomal luciferin were then evaluated in transgenic mice expressing luciferase. In contrast to rapid in vivo clearance of free luciferin (t 1/2 =3.54 min), luciferin encapsulated into long-circulating liposomes showed a prolonged release over 24 hours. The first order release rate constant of luciferin from longcirculating liposomes, as estimated from the best fit of the analytical model to the experimental data, was 0.01 h −1 . Insonation of luciferin-loaded temperature sensitive liposomes directly injected into one tumor of Met1-luc tumor-bearing mice resulted in immediate emission of light. Systemic injection of luciferin-loaded long-circulating liposomes into Met1-luc tumor-bearing mice, followed by unilateral ultrasound-induced hyperthermia, produced a gradual increase in radiance over time, reaching a peak 4-7 h post-ultrasound.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system

Kheirolomoom

Kruse

Qin

et al. 2010

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…This study showed that an EUD model incorporating dose heterogeneity in a tumour would be helpful in predicting responses from radiation nanomedicines. Medina et al ( 2007 ) described a method to visually and digitally show the spatial dose distribution in a tumour following i.t. injection of [ 186 Re]Re-BMEDA-liposomes (122 nm) in rats with s.c. SCC-4 human head and neck squamous cell carcinoma tumours.…”

Section: Main Textmentioning

confidence: 99%

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Reilly,

Georgiou,

Brown

et al. 2024

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background Radiation nanomedicines are nanoparticles labeled with radionuclides that emit α- or β-particles or Auger electrons for cancer treatment. We describe here our 15 years scientific journey studying locally-administered radiation nanomedicines for cancer treatment. We further present a view of the radiation nanomedicine landscape by reviewing research reported by other groups. Main body Gold nanoparticles were studied initially for radiosensitization of breast cancer to X-radiation therapy. These nanoparticles were labeled with 111In to assess their biodistribution after intratumoural vs. intravenous injection. Intravenous injection was limited by high liver and spleen uptake and low tumour uptake, while intratumoural injection provided high tumour uptake but low normal tissue uptake. Further, [111In]In-labeled gold nanoparticles modified with trastuzumab and injected iintratumourally exhibited strong tumour growth inhibition in mice with subcutaneous HER2-positive human breast cancer xenografts. In subsequent studies, strong tumour growth inhibition in mice was achieved without normal tissue toxicity in mice with human breast cancer xenografts injected intratumourally with gold nanoparticles labeled with β-particle emitting 177Lu and modified with panitumumab or trastuzumab to specifically bind EGFR or HER2, respectively. A nanoparticle depot (nanodepot) was designed to incorporate and deliver radiolabeled gold nanoparticles to tumours using brachytherapy needle insertion techniques. Treatment of mice with s.c. 4T1 murine mammary carcinoma tumours with a nanodepot incorporating [90Y]Y-labeled gold nanoparticles inserted into one tumour arrested tumour growth and caused an abscopal growth-inhibitory effect on a distant second tumour. Convection-enhanced delivery of [177Lu]Lu-AuNPs to orthotopic human glioblastoma multiforme (GBM) tumours in mice arrested tumour growth without normal tissue toxicity. Other groups have explored radiation nanomedicines for cancer treatment in preclinical animal tumour xenograft models using gold nanoparticles, liposomes, block copolymer micelles, dendrimers, carbon nanotubes, cellulose nanocrystals or iron oxide nanoparticles. These nanoparticles were labeled with radionuclides emitting Auger electrons (111In, 99mTc, 125I, 103Pd, 193mPt, 195mPt), β-particles (177Lu, 186Re, 188Re, 90Y, 198Au, 131I) or α-particles (225Ac, 213Bi, 212Pb, 211At, 223Ra). These studies employed intravenous or intratumoural injection or convection enhanced delivery. Local administration of these radiation nanomedicines was most effective and minimized normal tissue toxicity. Conclusions Radiation nanomedicines have shown great promise for treating cancer in preclinical studies. Local intratumoural administration avoids sequestration by the liver and spleen and is most effective for treating tumours, while minimizing normal tissue toxicity.

show abstract

“…Los liposomas son vesículas de dimensiones nanométricas formadas por una doble capa de fosfolípidos que encierran un espacio acuoso. Existen algunos estudios dosimétricos tanto teóricos [6,7] como experimentales [8,9] , así como algunos estudios preclínicos [10,11] que analizan el uso de complejos liposoma-radionúclido con nes terapéuticos, administrados por vía intravenosa o intratumoral en tumores sólidos. En el caso intratumoral, se ha encontrado que es ventajoso el mayor grado de localización y jación obtenido mediante la inyección directa en el tumor de los liposomas radiactivos, lo que se traduce en una dosis de radiación mayor en el tumor y menor en los tejidos sanos, así como una relajación del requisito de una distribución homogénea en todo el tumor debido al efecto de fuego cruzado de la radiación [12] ; a pesar de esto, la correcta determinación de la biodistribución de los liposomas radiactivos dentro del tejido tumoral sigue siendo un factor preponderante en la determinación de la distribución espacial de la dosis [8] .…”

Section: Introductionunclassified

Estimación computacional de la distribución interna de dosis absorbida en un tumor sólido a partir de imágenes tomográficas

Puchet

View full text Add to dashboard Cite

Spatial dose distributions in solid tumors from 186Re transported by liposomes using HS radiochromic media

Cited by 4 publications

References 18 publications

Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system

Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Estimación computacional de la distribución interna de dosis absorbida en un tumor sólido a partir de imágenes tomográficas

Contact Info

Product

Resources

About